MIT利用人工智能平台发现的新型超级抗生素,可以杀死多种抗药性细菌

2020-02-25 不详 MedSci原创

麻省理工学院的医学工程与科学研究所(IMES)的科研人员基于机器学习算法和人工智能(AI)发现了一种"功能强大"的新型抗生素化合物。

麻省理工学院的医学工程与科学研究所(IMES)的科研人员基于机器学习算法和人工智能(AI)发现了一种"功能强大"的新型抗生素化合物。

研究人员表示,在测试中,这种药物能够杀死多种致病细菌,包括一些对所有已知抗生素具有抗性的菌株,并在两种不同的小鼠模型中清除了感染

所使用的计算机模型旨在选择与现有药物不同的机制杀死潜在的细菌,并且可以在几天内筛选出超过一亿种化合物。

研究人员证实,他们还确定了其他几种有希望的抗生素候选药物,他们计划进一步测试这些候选药物,并认为该模型还可以基于其了解到的能够杀死细菌的化学结构,设计新药物。

麻省理工学院的医学工程与科学研究所(IMES)的泰米尔医学工程与科学教授James Collins说:"我们希望开发一个平台,使我们能够利用人工智能的力量开创抗生素药物发现的新时代。"

在过去的几十年中,很少开发出新的抗生素,并且大多数新批准的抗生素是现有药物的稍有不同的变体。当前用于筛选新抗生素的方法通常成本高得惊人,需要大量的时间投入。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057872, encodeId=9fdd205e872a6, content=<a href='/topic/show?id=40552481511' target=_blank style='color:#2F92EE;'>#人工智能平台#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24815, encryptionId=40552481511, topicName=人工智能平台)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Thu Dec 03 05:30:00 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058557, encodeId=0a3a205855e8b, content=<a href='/topic/show?id=995a58293a8' target=_blank style='color:#2F92EE;'>#新型超级抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58293, encryptionId=995a58293a8, topicName=新型超级抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 06 04:30:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900869, encodeId=74b81900869da, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Apr 21 01:30:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495391, encodeId=1b5b149539172, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Feb 27 07:30:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379672, encodeId=6e413e967220, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Feb 25 22:38:57 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057872, encodeId=9fdd205e872a6, content=<a href='/topic/show?id=40552481511' target=_blank style='color:#2F92EE;'>#人工智能平台#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24815, encryptionId=40552481511, topicName=人工智能平台)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Thu Dec 03 05:30:00 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058557, encodeId=0a3a205855e8b, content=<a href='/topic/show?id=995a58293a8' target=_blank style='color:#2F92EE;'>#新型超级抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58293, encryptionId=995a58293a8, topicName=新型超级抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 06 04:30:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900869, encodeId=74b81900869da, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Apr 21 01:30:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495391, encodeId=1b5b149539172, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Feb 27 07:30:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379672, encodeId=6e413e967220, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Feb 25 22:38:57 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057872, encodeId=9fdd205e872a6, content=<a href='/topic/show?id=40552481511' target=_blank style='color:#2F92EE;'>#人工智能平台#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24815, encryptionId=40552481511, topicName=人工智能平台)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Thu Dec 03 05:30:00 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058557, encodeId=0a3a205855e8b, content=<a href='/topic/show?id=995a58293a8' target=_blank style='color:#2F92EE;'>#新型超级抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58293, encryptionId=995a58293a8, topicName=新型超级抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 06 04:30:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900869, encodeId=74b81900869da, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Apr 21 01:30:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495391, encodeId=1b5b149539172, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Feb 27 07:30:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379672, encodeId=6e413e967220, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Feb 25 22:38:57 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-04-21 gracezdd
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057872, encodeId=9fdd205e872a6, content=<a href='/topic/show?id=40552481511' target=_blank style='color:#2F92EE;'>#人工智能平台#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24815, encryptionId=40552481511, topicName=人工智能平台)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Thu Dec 03 05:30:00 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058557, encodeId=0a3a205855e8b, content=<a href='/topic/show?id=995a58293a8' target=_blank style='color:#2F92EE;'>#新型超级抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58293, encryptionId=995a58293a8, topicName=新型超级抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 06 04:30:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900869, encodeId=74b81900869da, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Apr 21 01:30:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495391, encodeId=1b5b149539172, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Feb 27 07:30:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379672, encodeId=6e413e967220, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Feb 25 22:38:57 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-02-27 songbq
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057872, encodeId=9fdd205e872a6, content=<a href='/topic/show?id=40552481511' target=_blank style='color:#2F92EE;'>#人工智能平台#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24815, encryptionId=40552481511, topicName=人工智能平台)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Thu Dec 03 05:30:00 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2058557, encodeId=0a3a205855e8b, content=<a href='/topic/show?id=995a58293a8' target=_blank style='color:#2F92EE;'>#新型超级抗生素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58293, encryptionId=995a58293a8, topicName=新型超级抗生素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Sep 06 04:30:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900869, encodeId=74b81900869da, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Apr 21 01:30:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495391, encodeId=1b5b149539172, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Thu Feb 27 07:30:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379672, encodeId=6e413e967220, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Tue Feb 25 22:38:57 CST 2020, time=2020-02-25, status=1, ipAttribution=)]
    2020-02-25 qingfengqishi5

    学习了,学习了

    0

相关资讯

青年才俊!MIT公布:“35名35岁以下创新者”榜单,生物医药占10席

6月28日,《麻省理工科技评论》一年一度的“35名35岁以下创新者” (35 Innovators Under 35)榜单最新出炉,其中,共有10名生物医药行业的年轻领袖位列其中;同时,有6位华人入选这份重量级榜单。

Nat Commun:妙!MIT 大牛发明「纳米狗」撕扯癌细胞,大幅提升药物战斗力

1959 年,著名的物理学家 Richard Feynman 在加州技术研究所做了一个演讲,题目为「There’s Plenty of Room at the Bottom」。演讲中他设想了一种非常小的微粒,小到可以在细胞水平控制,这就是纳米颗粒的“雏形”。随着纳米技术的发展,近年来,越来越多的领域都有了它的身影,其中就

Angewandte Chemie: MIT新突破——可提高mRNA疗法效率达4倍

通过将称为信使RNA(mRNA)的遗传物质输送到细胞中,科学家们可以诱导细胞产生由mRNA编码的任何蛋白质。这种技术具有很大的潜力来发展疫苗或治疗诸如癌症的疾病,但是实现mRNA的有效递送是实现其临床转化的一大挑战。

冷冻大脑让意识“永生”?麻省理工学院和这家公司合作受批评

冷冻大脑以期在未来获得永生并不新鲜。不过美国初创公司Nectome目前在探索另一条新的途径,他们提倡对人实施安乐死,并通过“上传大脑”将思想实现永久的数字化保存。

Nat Methods:逆天!MIT 大牛用尿布材料将大脑尺寸扩大了 20 倍

近日,《自然》子刊《Nature Methods》上发表了一篇论文,而它立刻得到了《科学》官网的报道,这是重磅新闻才能享受的殊荣。这则被两家顶尖学术期刊共同关注的研究出自 MIT 的著名科学家 Ed Boyden 教授之手。他的团队发明的“大脑倍增术”将大脑尺寸扩大了 20 倍,让神经学家能在普通的光学显微镜下,以极高的分辨率观察大脑结构,甚至清晰地分辨出不同的突触蛋白。▲Ed Boyden

Cell Reprots:MIT大神科学家蔡理慧在神经修复领域取得新突破,有望找回阿尔兹海默病患者失去的记忆

记忆是人类适应其生存环境所需要的最基本能力,也是人们最宝贵的财富。然而,每年有许许多多的人因为阿尔兹海默病(AD)或者意外事故而丧失记忆,对患者以及家人造成了严重的影响。那么有没有办法帮助这些人恢复丧失的记忆呢?